Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
IRVINE, Calif., Dec. 06, 2016 -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today it will participate at the Guggenheim Securities 4th Annual Boston Healthcare Conference in Boston, MA. This conference will allow institutional investors to meet with the Company but does not include a formal presentation.
| Event: | Guggenheim Securities 4th Annual Boston Healthcare Conference | |||||||
| Date: | Tuesday, December 13, 2016 | |||||||
| Participant: | John McDermott, Chief Executive Officer |
About Endologix, Inc.
Endologix, Inc., develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the United States. Additional information can be found on Endologix's website at www.endologix.com.
COMPANY CONTACT: Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020
